Further RCTs in this setting will be ethically challenging, underscoring the value of registry data like these, experts agreed.

The high rate of MI in the study worried some physicians, but investigators say the events have no impact on prognosis.

The bioresorbable-polymer, ultrathin-strut design may help DES break through their current safety and efficacy plateau.

Still, given the limitations of the study, clinicians should continue giving IV tPA in eligible patients, Bruce Ovbiagele says.

Some of the dilatation catheters are not deflating properly. One patient has died from postprocedural complications.

New data should be a call to action to better understand the underlying causes, as SCD rates rebound in women.

New research shows good collaterals also delayed the ED trip, likely because patients had less pain and ischemia, experts said.

In high-risk patients, rivaroxaban and warfarin plus aspirin were similarly protective against thromboembolic events.

Experts reacting to the data, updated with COMPLETE, had some caveats and expressed surprise at the lack of an MI reduction.

The oral, once-daily, non-statin drug was cleared for adults with heterozygous familial hypercholesterolemia or established ASCVD.

Part two of the EXTEND-IA TNK trial shows no advantage to using a 0.40-mg/kg dose instead of a 0.25-mg/kg dose.

The latest revelations say the DSMB and the ESC had mortality concerns that weren’t shared, but the ESC disputes this.